CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 3 enrolled
Drug / intervention
ASN51drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06390098
NCT06390098Phase 1Completed
CompareCT.gov

A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Adult Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51 Following a Single Oral Dose

Asceneuron S.A.·interventional·Posted Apr 30, 2024·Updated May 8, 2025

In Brief

A Phase 1 clinical trial evaluating ASN51 for Healthy Participants. Completed, enrolled 3 participants across 1 site.

Detailed Summary

This is a phase 1, open-label, positron emission tomography (PET) study in healthy adult participants to determine the relationship between plasma concentration and brain target occupancy of ASN51 following a single oral dose.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited Kingdom
CollaboratorsHammersmith Medicines Research Invicro

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedApr 30, 2024
Enrollment StartAug 9, 2021
Primary CompletionOct 12, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 2.2 years ago

Interventions

ASN51drug

Oral